Healthcare Is Getting Smarter — And Riskier

Good morning, ! Healthcare’s AI adoption is accelerating—but the real bottleneck isn’t the technology. It’s everything around it: integration, governance, regulation, and cybersecurity.

This week, we look at where healthcare’s digital transformation is creating the most value—and where the infrastructure, regulation, and cybersecurity challenges could get in the way.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

Join PE150 and Caplink for our AI & Data Insight Breakfast in London. Register here.

DATA DIVE

The Real Bottleneck Isn’t AI. It’s Integration.

Healthcare is moving past the question of whether to deploy AI. The harder question is whether these systems can actually be embedded into the workflows that run the industry.

The biggest obstacle to scaling generative AI is integration: 59% of healthcare leaders cite difficulties adapting AI to existing workflows. Risk follows at 43%, while lack of internal capabilities and insufficient data or technology infrastructure each affect 31%.

The risk profile is equally telling. 66% of leaders remain concerned about model inaccuracies, bias or flaws, while 60% flag security risks, 52% regulatory compliance and 49% ethics and privacy.

That creates an important distinction for investors and operators: the next winners may not be the companies with the most sophisticated models, but those that can integrate AI into legacy workflows without compromising control, compliance or trust.

In healthcare, autonomy creates value only when it can be governed. The technology is scaling faster than the infrastructure required to safely absorb it.

Read more

HEALTHTECH CORNER

Digital Neuro Biomarkers Move Toward Clinical Scale

Digital neurological biomarkers are moving from experimental endpoints toward a potentially meaningful layer of clinical infrastructure. The market is projected to expand from $1.7B in 2025 to $6.9B by 2036, roughly quadrupling as software, wearables, and connected devices make neurological measurement more continuous and scalable.

The opportunity is not simply more data. Digital biomarkers could give providers and drug developers a way to measure changes in cognition, movement, sleep, and other neurological signals outside episodic clinical visits. That creates potential value across remote monitoring, trial endpoints, patient stratification, and earlier detection.

But market growth will not guarantee clinical adoption. The key constraint is validation. Vendors that can demonstrate reproducibility, regulatory credibility, and integration into clinical workflows should capture disproportionate value, while biomarkers without clear decision utility risk remaining research tools.

Why it matters: A 4x market expansion suggests neurological care is becoming increasingly measurable outside the clinic. For investors and operators, the defensible layer may be less about collecting signals and more about proving which signals clinicians and biopharma can actually trust. (More)

PRESENTED BY CAPLINK X PE 150

You’re invited: Where AI Meets Private Equity

Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.

On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.

The morning will feature three practitioner-led discussions:

• AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies. Sponsored by Exact Insight.

• AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management. Sponsored by our M&A Technology Partner Datasite.

• Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.

Interested in attending? Register or request the full agenda here.

Interested in sponsoring? Email [email protected] 

COMPLIANCE CORNER

Healthcare’s Regulatory Map Is Getting Harder to Navigate

For pharma, compliance is becoming less about keeping up with individual rules and more about navigating an increasingly fragmented global regulatory environment.

IQVIA highlights how pricing, market access, trade policy and R&D incentives are diverging across major markets, creating a more complex operating landscape for Life Sciences companies. The U.S., Europe and China are increasingly pursuing different approaches to drug pricing, manufacturing and innovation policy.

This matters because regulatory decisions are no longer confined to the legal department. They can influence where companies invest in R&D, how they price medicines, where they manufacture, and ultimately how quickly products reach patients.

For investors, the implication is straightforward: regulatory exposure should increasingly be treated as a strategic and valuation variable, not simply a compliance cost.

Bottom line: In 2026, understanding the regulatory map may be just as important as understanding the competitive landscape.

Read more

COMPETITIVE LANDSCAPE SNAPSHOT

TREND TO WATCH

Healthcare’s Cyber Risk Is Becoming a Balance-Sheet Risk

Healthcare’s digital transformation is creating a new vulnerability: the more connected the system becomes, the larger the blast radius when something goes wrong. KPMG’s latest healthcare cyber-risk outlook frames cybersecurity as no longer an IT problem, but an enterprise-level business risk for payers and providers.

The timing matters. AI, cloud platforms, connected medical devices and increasingly complex third-party ecosystems are expanding the attack surface while making healthcare operations more dependent on digital infrastructure. A cyber incident can now mean more than stolen data—it can disrupt clinical operations, delay care and create material financial and reputational damage.

For investors, this changes the diligence checklist. Cybersecurity maturity is increasingly part of enterprise value, particularly for tech-enabled providers, digital health companies and businesses dependent on critical third-party infrastructure.

The takeaway: healthcare’s digitalization is creating efficiency—and a new category of risk that capital markets can no longer treat as an afterthought.

Read more

INTERESTING ARTICLES